BridgeBio Pharma Inc. will report fourth-quarter and full-year 2025 results after the market closes on Tuesday, February 24, a closely watched print for a rare-disease developer seeking to prove its ...
Investor's Business Daily on MSN
BridgeBio unveils positive results for its most 'hotly debated' phase 3 drug
BridgeBio unveiled promising results Thursday for its "hotly debated" final-phase asset: a potential treatment for achondroplasia.
The latest in a string of clinical wins, the late-stage data gives the company strong footing to compete with BioMarin's top seller.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results